103 related articles for article (PubMed ID: 3283619)
1. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J
Onkologie; 1988 Feb; 11(1):10-2. PubMed ID: 3283619
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
3. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Donhuijsen-Ant R; Planker M; Wendt FC; Büchner T
Onkologie; 1987 Feb; 10(1):11-2. PubMed ID: 3295619
[TBL] [Abstract][Full Text] [Related]
5. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
[TBL] [Abstract][Full Text] [Related]
6. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
Leuk Lymphoma; 1993; 10 Suppl():133-7. PubMed ID: 8481662
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
[TBL] [Abstract][Full Text] [Related]
9. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Hiddemann W; Schleyer E; Uhrmeister C; Aul CH; Maschmeyer G; Heinecke A; Büchner T
Cancer Treat Rev; 1990 Sep; 17(2-3):279-85. PubMed ID: 2272043
[TBL] [Abstract][Full Text] [Related]
10. Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Hiddemann W; Aul C; Maschmeyer G; Lathan B; Köppler H; Hoffmann R; Grüneisen T; Donhuijsen-Ant R; Ludwig WD; Balleisen L
Onkologie; 1989 Feb; 12(1):4-6. PubMed ID: 2654790
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Ann Hematol; 2001 Jun; 80(6):334-9. PubMed ID: 11475146
[TBL] [Abstract][Full Text] [Related]
12. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
13. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Cuttner J; Holland JF
Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
[TBL] [Abstract][Full Text] [Related]
14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
Walters RS; Kantarjian HM; Keating MJ; Plunkett WK; Estey EH; Andersson B; Beran M; McCredie KB; Freireich EJ
Cancer; 1988 Aug; 62(4):677-82. PubMed ID: 3165047
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
17. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
19. Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Hiddemann W; Aul HC; Maschmeyer G; Urbanitz D; Lathan B; Reichle A; Köppler H; Donhuijsen-Ant R; Ludwig WD; Grüneisen T
Haematol Blood Transfus; 1990; 33():604-10. PubMed ID: 2182450
[No Abstract] [Full Text] [Related]
20. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J; Amler S; Kreuzer KA; Spiekermann K; Lindemann HW; Lengfelder E; Graeven U; Staib P; Ludwig WD; Biersack H; Ko YD; Uppenkamp MJ; De Wit M; Korsten S; Peceny R; Gaska T; Schiel X; Behringer DM; Kiehl MG; Zinngrebe B; Meckenstock G; Roemer E; Medgenberg D; Spaeth-Schwalbe E; Massenkeil G; Hindahl H; Schwerdtfeger R; Trenn G; Sauerland C; Koch R; Lablans M; Faldum A; Görlich D; Bohlander SK; Schneider S; Dufour A; Buske C; Fiegl M; Subklewe M; Braess B; Unterhalt M; Baumgartner A; Wörmann B; Beelen D; Hiddemann W;
Leukemia; 2018 Dec; 32(12):2558-2571. PubMed ID: 30275528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
